Akumentis Healthcare posts Rs 66 Cr profit in FY25, revenue grows 9%

Akumentis Healthcare, a pharmaceutical company, reported a profit of Rs 66 crore in the fiscal year ending March 2025, marking a 16.8% increase compared to FY24. The company achieved this growth on the back of consistent revenue and controlled operating costs.

Akumentis’ revenue from operations grew by 9% to Rs 433.5 crore in FY25 from Rs 398 crore in FY24, according to its financial statement sourced from the Registrar of Companies (RoC).

Akumentis Healthcare operates on a branded formulations model, focusing on prescription-driven pharmaceuticals across therapeutic areas such as cardiology, dermatology, orthopedics, and gynecology. Sale of the products was the sole source of revenue.

On the expense side, the cost of materials rose by 7.6% to Rs 113 crore in FY25 from Rs 105 crore in FY24. Employee benefit expenses increased by 8% to Rs 132 crore, while advertising expenses remained flat at Rs 39 crore. Travelling expenses rose 7% to Rs 30 crore, whereas legal and professional fees surged 25% to Rs 20 crore during the year.

Overall, Akumentis’ total expenses grew nearly 9% to Rs 361.5 crore in FY25 from Rs 333 crore in FY24. For a more detailed expense breakup, head to TheKredible.

The combination of steady top-line growth and measured spending helped the company expand profitability. Akumentis’ profit rose by 17% to Rs 66 crore in FY25 from Rs 56.5 crore in FY24. Its ROCE and EBITDA margin stood at 43.70% and 19.91% respectively.

On a unit level, the company spent Rs 0.83 to earn a rupee during FY25. The company recorded current assets worth Rs 167 crore in FY25, including Rs 92 crore in cash and bank balances.

According to TheKredible, Akumentis has raised a total of $19 million of funding till date, with Peak XV Partners as its lead investor.